The British Columbia Cancer Agency has purchased RainDance Technologies' ThunderStorm microdroplet PCR platform for use in its Clinical Diagnostic Genomics group, the company said this week.
According to RainDance, over the next two years, BCCA researchers plan to sequence cancer predisposition genes in more than 2,000 samples from patients with a hereditary predisposition to various types of cancer. The researchers want to use that data to guide clinical management.